Part of the UT Health Science Center
The Cancer Therapy & Research Center is the answer for cancer
A Cancer Center designated by the National Cancer Institute
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of VB-111 Combined with Bevacizumab vs. Bevacizumab Monotherapy in Patients with Recurrent Glioblastoma (CTMS# 15-2078)
This is a phase 3, randomized, multicenter study to compare VB-111 plus bevacizumab to bevacizumab in adult patients with recurrent Glioblastoma.
To enroll or if you have questions about participation
Type of Cancer Treated